Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17997487 | 0.83 | DYRK1A (0.36) | ENPP2 | |
| SCHEMBL15940842 | 0.78 | ENPP2 (0.50) | ENPP2 | |
| SCHEMBL23732879 | 0.76 | KMT2A (0.41) | ENPP2 | |
| SCHEMBL1303307 | 0.76 | LPL (0.48) | ENPP2 | |
| Hydrochloric Acid SCHEMBL29955592 | 0.76 | ENPP2 (0.48) | ENPP2 | |
| SCHEMBL28967087 | 0.73 | ENPP2 (0.36) | ENPP2 | |
| SCHEMBL12831165 | 0.73 | MAPT (0.40) | — | |
| SCHEMBL9952165 | 0.73 | ENPP2 (0.34) | ENPP2 | |
| SCHEMBL2067301 | 0.72 | CYP11B2 (0.42) | ENPP2 | |
| SCHEMBL17556274 | 0.72 | CHRNB2 (0.43) | THRBENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10517872-B2 | Pyridazinone macrocycles as IRAK inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2019-12-31 | — | — | US | disclosed |
| US-20170173019-A1 | PYRIDAZINONE MACROCYCLES AS IRAK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2017-06-22 | — | — | US | disclosed |
| US-20170173019-A1 | PYRIDAZINONE MACROCYCLES AS IRAK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10517872-B2 | Pyridazinone macrocycles as IRAK inhibitors and uses thereof | IRAK2, IRAK1, IRAK3 | THRB 1100/4885IDO1 1631/4885ENPP2 1882/4885 |
| US-20170173019-A1 | PYRIDAZINONE MACROCYCLES AS IRAK INHIBITORS AND USES THEREOF | IRAK2, IRAK1, IRAK3 | THRB 1100/4885IDO1 1631/4885ENPP2 1882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.